DENTSPLY SIRONA (NASDAQ: XRAY) has been downgraded from Zacks investment research from a “buy” note to a “keep” note in a report published on Monday, Zacks.com reports. They currently have a price target of $ 68.00 on the medical device vendor’s inventory. Zacks investment researchThe company’s price target suggests a potential rise of 4.76% from the company’s current price.
According to Zacks, “DENTSPLY SIRONA saw growth in both consumables and technology and equipment in the first quarter of 2021, driven by a stronger than expected recovery in global dental demand. Its strategic acquisitions of Byte and Datum Dental are major positive elements. When the first quarter 2021 results were announced, the company’s R&D was significantly increased in 2021 and, according to management, this trend is expected to continue in the near future. A raised financial outlook for 2021 gives cause for optimism. A strong liquidity position is an added advantage. The company’s first quarter results were better than expected. DENTSPLY SIRONA shares have outperformed their industry over the past six months. Still, the company saw lower organic sales in its Technology and Equipment segment during the quarter. The Forex problems have also presented a challenge for the company. “
Other equity research analysts have also recently published research reports on the company. Piper Sandler raised her price target on DENTSPLY SIRONA from $ 70.00 to $ 75 and gave the stock an “overweight” rating in a research report on Thursday, May 6th. HC Wainwright increased its price target on DENTSPLY SIRONA from $ 60.00 to $ 72.00 and rated the company as “neutral” in a report released on Friday May 7th. Barclays increased its price target on DENTSPLY SIRONA from $ 50.00 to $ 55.00 and rated the company “underweight” in a report released on Tuesday March 2nd. Barrington Research increased its price target on DENTSPLY SIRONA from $ 71.00 to $ 77.00 and gave the company an “outperformance” rating in a report released on Friday, May 7th. Finally, Robert W. Baird increased his price target on DENTSPLY SIRONA from $ 71.00 to $ 78.00 and gave the company an “outperformance” rating in a report released on Friday May 7th. One investment analyst gave the stock a sell rating, four assigned a conservation rating, and five assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $ 64.44.
XRAY stock traded up $ 1.73 in Monday’s session, reaching $ 64.91. 13,791 shares of the stock traded for an average volume of 1,570,963. The company’s 50-day simple moving average is $ 66.42. DENTSPLY SIRONA has a 52 week low of $ 40.15 and a 52 week high of $ 69.54. The company has a rapid ratio of 0.99, a current ratio of 1.40, and a debt ratio of 0.39. The company has a market cap of $ 14.17 billion, a price / earnings ratio of 82.16, a PEG ratio of 1.06 and a beta of 0.93.
DENTSPLY SIRONA (NASDAQ: XRAY) last released its quarterly results on Thursday, May 6. The medical device supplier reported earnings per share (EPS) of $ 0.72 for the quarter, beating Zacks’ consensus estimate of $ 0.55 by $ 0.17. DENTSPLY SIRONA recorded a return on equity of 9.45% and a net margin of 4.99%. The company posted revenue of $ 1.03 billion in the quarter, compared to a consensus estimate of $ 944.89 million. In the same quarter of the previous year, the company achieved earnings per share of $ 0.43. The company’s quarterly revenue increased 17.5% from the same quarter last year. Equity research analysts predict that DENTSPLY SIRONA will post 2.86 EPS for the current year.
In other DENTSPLY SIRONA news, insider Walter Petersohn sold 17,425 shares of the company in a trade that took place on Tuesday, May 25. The stock was sold at an average price of $ 67.40, for a total trade of $ 1,174,445.00. As a result of the sale, the insider now owns 55,222 shares of the company, valued at $ 3,721,962.80. The sale was disclosed in a legal file with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.69% of the company’s shares.
Several institutional investors have recently changed their positions in the company. Prentiss Smith & Co. Inc. acquired a new equity interest in DENTSPLY SIRONA during the 1st quarter valued at approximately $ 4,307,000. B. Metzler seel. Sohn & Co. Holding AG increased its position in DENTSPLY SIRONA shares by 23.7% in the first quarter. B. Metzler seel. Sohn & Co. Holding AG now owns 21,415 shares of the medical device supplier valued at $ 1,366,000 after purchasing an additional 4,097 shares during the period. The Canada Pension Plan Investment Board increased its position in DENTSPLY SIRONA shares by 259.1% during the 1st quarter. The Canada Pension Plan Investment Board now owns 357,313 shares of the medical device supplier valued at $ 22,800,000 after purchasing an additional 257,799 shares during the period. Point72 Asset Management LP acquired a new stake in the shares of DENTSPLY SIRONA during the 1st quarter valued at approximately $ 7,150,000. Finally, Eaton Vance Management increased its position in DENTSPLY SIRONA shares by 6.3% during the first quarter. Eaton Vance Management now owns 13,593 shares of the medical device supplier valued at $ 867,000 after purchasing an additional 806 shares during the period. Institutional investors and hedge funds hold 94.50% of the company’s shares.
About DENTSPLY SIRONA
DENTSPLY SIRONA Inc designs, develops, manufactures, distributes and sells various dental products and technologies primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylactic pastes, dental sealants, impression and restorative materials, tooth whiteners and topical fluoride products; and small equipment products include intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.
Read more: What is a conference call?
For more information on Zacks Investment Research’s research offerings, visit Zacks.com
This instant news alert was powered by storytelling technology and financial data from MarketBeat to provide readers with the fastest, most accurate reports. This story was reviewed by the MarketBeat editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Featured article: Which member countries make up the G-20?
7 lithium stocks that will fuel the electric vehicle boom
The demand for lithium is expected to increase exponentially in the coming years. In fact, according to Statista, demand for lithium could very well double to 820,000 tonnes by then. Part of that demand will come from the companies that make the batteries we use every day. For example, lithium is an essential component of the batteries that power our mobile devices.
But real growth will come as the United States invests in electric vehicles (EVs). The Biden administration recently announced its intention to convert the US government’s fleet of more than 600,000 vehicles to electric vehicles.
And as you know, electric vehicle stocks are in a kind of bubble right now. This is in part due to the growing number of companies that went public over the past year. However, as investors are starting to realize, not all of these companies will be the next Tesla. In fact, some of these companies might never succeed in bringing an EV to market, at least not on the scale required.
Those who make it will need lithium and a lot. To help you sift through the best lithium stocks to buy, we’ve put together this special overview.
Check out the “7 Lithium Stocks That Will Power The Electric Vehicle Boom”.